Sheng Ding, PhD

Senior Investigator

William K. Bowes, Jr. Distinguished Investigator

Phone: (415) 734-2717
Fax: (415) 355-0141
Fewer scientific details, please
Download a Printable PDF

Other Professional Titles

Investigator, Roddenberry Center for Stem Cell Biology and Medicine at Gladstone

Professor, Pharmaceutical Chemistry, University of California, San Francisco

Administrative Assistant

Audrey Le
(415) 734-2768
audrey.le@gladstone.ucsf.edu

More about Dr. Ding

Dr. Ding has pioneered the development and application of innovative chemical approaches to stem cell biology and regeneration. His work has focused on discovering and characterizing novel small molecules that can control various cell fates and functions, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues.

In 2004, Dr. Ding was named Assistant Professor of Chemistry at The Scripps Research Institute. He has published over 70 research articles, reviews and book chapters, and has made several seminal contributions to the stem cell field.

Dr. Ding is a member of several professional groups, including the American Chemical Society, the American Society for Cell Biology and the International Society for Stem Cell Research. He has received a variety of honors, including being named one of the top five people of 2009 by The Scientist.

Dr. Ding earned a bachelor’s degree in chemistry with honors from the California Institute of Technology in 1999, working with Robert H. Grubbs, PhD. In 2003, he earned a PhD in chemistry from The Scripps Research Institute, working with Peter G. Schultz, PhD.

 

More scientific details, please

Other Professional Titles

Investigator, Roddenberry Center for Stem Cell Biology and Medicine at Gladstone

Professor, Pharmaceutical Chemistry, University of California, San Francisco

Administrative Assistant

Audrey Le
(415) 734-2768
audrey.le@gladstone.ucsf.edu

Areas of Investigation

Our laboratory is interested in developing and applying innovative chemical approaches to stem cell biology and regeneration. Our work focuses on discovering and characterizing novel small molecules that can control cell fate and function of various cell types, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues.

Current Lab Focus

Our current works have focused on screening the chemical libraries to identify and further characterize small molecules that can control stem cell fate in various systems, including

  • Self-renewal regulation of embryonic and adult stem cells;
  • Directed and step-wised differentiation of embryonic stem cells toward neuronal, cardiac and pancreatic lineages;
  • Subtype specification of human tissue-specific stem/progenitor cells;
  • Cellular plasticity and reprogramming of lineage-restricted somatic cells to alternative cell fate (e.g., toward iPSCs or transdifferentiation);
  • Functional proliferation of adult cardiomyocytes and pancreatic beta cells;
  • Developmental signaling pathways (i.e. Wnt, Hh, BMP and FGF) and epigenetic mechanisms (histone and DNA de/methylation); and
  • Development of new technologies for drug discovery.

Joined Gladstone

2011

Why Gladstone?

Gladstone has both the expertise and focus to spur the transformative discoveries that will lead to treatments for devastating diseases.

Key Achievements

  • Developed the first protein-transduction technology for induced pluripotent stem cell (iPSC) reprogramming and generated the first protein-induced pluripotent stem (piPS) cells from somatic cells without using any genetic materials. This method and such piPS cells provide safer cells for personalized regenerative medicine and more effective platform for human disease modeling.
  • First discovered a series of small molecules and conditions that can replace reprogramming transcription factors and enhance reprogramming efficiency in generating iPS cells from somatic cells.
  • Developed a novel-reprogramming paradigm for generating heart, brain and pancreatic cells directly from skin fibroblasts.
  • First developed a method for generating a novel type of human pluripotent stem cells that represents an earlier pluripotency (naïve) stage and a true equivalent of classic murine ESCs. These novel human pluripotent stem cells may serve as better materials for regenerative medicine.
  • First identified a number of different synthetic small molecules that can control cell fate, including stem cell self-renewal, differentiation, lineage-specific reprogramming and developmental and disease pathways.

Education

California Institute of Technology (BS), Chemistry (1999)
The Scripps Research Institute (PhD), Chemistry (2003)

Affiliations

Fate Therapeutics, Inc., Co-founder and Member of Scientific Advisory Board
Stemgent, Inc., Co-founder and Member of Scientific Advisory Board
American Chemical Society 

American Society for Cell Biology 

International Society for Stem Cell Research 


Editorial Board, Journal of Medical Chemistry
Editorial Board, Journal of Biological Chemistry
Editorial Board, Stem Cells Translational Medicine
Editorial Board, Stem Cells Reviews and Reports

Awards

  • New Faculty Award, California Institute for Regenerative (2008)
  • Prostate Cancer Foundation Challenge Award (2008)
  • #1 of Top 10 Innovations, and Top 5 People in 2009 by The Scientist Magazine (2009)
  • Named as one of the 100 most inspiring people in the life sciences industry by PharmaVoice (2010)
  • NIH transformative R01 (2010)
  • Named one of the San Francisco Business Times 40 Under 40 “visionaries and game changers ... whose imagination, innovation, and leadership will usher the Bay Area into its next phase of prosperity.” (2012)
Syndicate publications

Featured Publications

Sheng Ding, PhDEfe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, Chen J, Ding S. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol. 2011 Mar;13(3):215-22. View in: PubMed
Sheng Ding, PhDKim J, Efe JA, Zhu S, Talantova M, Yuan X, Wang S, Lipton SA, Zhang K, Ding S. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7838-43. Epub 2011 Apr 26. View in: PubMed